ABVC BioPharma Announces Completion of Subject Recruitment for Interim Analysis on ADHD Phase 2b Clinical Study
ABVC BioPharma, Inc. recently announced an update on the company’s 8-week long ADHD Phase 2b clinical study taking place at the University of California San Francisco (UCSF) Medical Center and five Taiwanese medical centers. 69 subjects enrolled in the study, 50 completed the study, and 11 are currently undergoing treatment.
The study, titled A Phase 2b Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients With Adult Attention-Deficit/Hyperactivity Disorder is a randomized, double-blind, placebo-controlled study involving a total of approximately 100 patients in the US and Taiwan. The Phase 2b clinical study continues the Phase 2a clinical study of ABV-1505. Phase 2a successfully achieved the specified primary endpoints at UCSF and was accepted by the US FDA in October 2020.
“We received a favorable response from the subjects participating in our ADHD Phase 2b study at all of our sites,” said ABVC BioPharma Chief Executive Officer Uttam Patil, PhD. “To reach an interim analysis, the study requires 69 patients’ data. Our clinical trials continue to demonstrate that medicine derived from plants can have significant therapeutic benefits, often with few – if any – side effects. We expect to report similar results in our interim analysis report.”
According to the Polaris market research report, the global ADHD treatment market was valued at $16.13 billion in 2022 and is expected to reach $32.14 billion by 2030 with a CAGR of 7.1% over the forecast period.
ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. For its drug products, the company utilizes in-licensed technology from its network of world-renowned research institutions to conduct proof-of-concept trials through Phase 2 of clinical development. ABVC BioPharma’s network of research institutions includes Stanford University, the University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus, the company intends to conduct global clinical trials through Phase 3.
Total Page Views: 1373
